An open-label phase II study (ACNS0126) testing the efficacy of chemoradiotherapy with @entity2903 ( @entity2904 ) followed by adjuvant @entity2904 was conducted by the @entity1 's Oncology Group. During the period from July 6, 2004 through September 6, 2005, 63 @entity1 with newly diagnosed @entity11 ( @entity11 ) were enrolled in the study. All @entity1 received @entity2904 at a dosage of 90 mg/m(2)/day for 42 days to a dose of 59.4 Gy. Four weeks following irradiation, @entity2904 was given at a dosage of 200 mg/m(2)/day for 5 days every 28 days, for a total of 10 cycles. The primary objective of the statistical analysis was to determine whether the current treatment produced a 1-year event-free survival (EFS) rate higher than the historical baseline of 21.9% observed in CCG-9941. The mean 1-year EFS (   standard deviation) was 14%    4.5%, compared with 21.9%    5% for CCG-9941. The P value of the test of comparison of 1-year EFS, based on a 1-sided, 1-sample test of proportions, was .96. There was no evidence that @entity2903 produced a 1-year EFS rate higher than 21.9%. The mean 1-year OS (   standard deviation) was 40%    6.5%, compared with 32%    6% for CCG-9941. The median time to death was 9.6 months. Chemoradiotherapy with @entity2904 followed by adjuvant @entity2904 is not more effective than previously reported regimens for the treatment of @entity1 with @entity11 .

@entity2903 in the treatment of XXXX with newly diagnosed @entity11 : a report from the @entity1 's Oncology Group.

@entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity2904 :: ('CHEBI:72564', 'Chemical') :: ['TMZ'] @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children'] @entity11 :: ('MESH:D005910', 'Disease') :: ['diffuse intrinsic pontine glioma', 'DIPG']
@entity1 :: (9606,Species) :: ['children']
